Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8932557 | AVID RADIOPHARMS INC | Imaging agents for detecting neurological dysfunction |
May, 2032
(8 years from now) |
Tauvid is owned by Avid Radiopharms Inc.
Tauvid contains Flortaucipir F-18.
Tauvid has a total of 1 drug patent out of which 0 drug patents have expired.
Tauvid was authorised for market use on 28 May, 2020.
Tauvid is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Tauvid from 2024-05-28.
The generics of Tauvid are possible to be released after 26 May, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2025 |
Drugs and Companies using FLORTAUCIPIR F-18 ingredient
NCE-1 date: 2024-05-28
Market Authorisation Date: 28 May, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS